帕他色替双盐酸盐新

参考资料仅供科学研究，不可用于个人用途。

货号：BCP23821CAS号：1396257-94-5纯度：98%

在线咨询

购买咨询

全国免运费！免费咨询：400-099-8200 或手机联系：13472751340

* 必填项

请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS号	1396257-94-5	货号	BCP23821
中文名	帕他色替双盐酸盐
英文名	Ipatasertib dihydrochloride
中文别名	双盐酸帕他色替;
英文别名	GDC0068 2HCl;Ipatasertib 2HCl;GDC0068 dihydrochloride;GDC-0068 dihydrochloride; RG-7440 dihydrochloride;
SMILES	CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O.Cl.Cl
化学名称
分子式	C24H34Cl3N5O2	分子量	530.92
纯度	98%	配送	惯例下常温包邮
产品描述	Ipatasertib is typically efficacious in xenograft models in which Akt is activated because of genetic alterations including PTEN loss, PIK3CA mutations/amplifications, or HER2 overexpression. In these models, tumor growth delay, stasis, or regression is achieved at or below 100 mg/kg daily oral dose, which is the maximum dose tested in immunocompromised mice that is well tolerated. When tested in vivo, daily dosing of Ipatasertib in combination with Docetaxel induces tumor regression and stasis in the PC-3 and MCF7-neo/HER2 xenograft models, at doses where each single agent is ineffective or only causes modest tumor growth delay. Similarly, increased TGI is observed in the OVCAR3 ovarian cancer xenograft model when Ipatasertib is combined with Carboplatin. The combination of Ipatasertib with Docetaxel or Carboplatin is tolerated with less than 5% body weight loss when compared with treatment with each chemotherapeutic agent alone.

帕他色替双盐酸盐 新